Womble Bond Dickinson US LLP

General

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Cases1246

Challenger50%

Patent Owner50%

NPE50%

lewisroca

lrrc.com

Practice Areas

Transport., E-Comm.Mech Eng, ManufBiotech

Top Attorneys

Patrick J. CoyneNeal S. CohenPeter Kinsella

Elite Ratings

DCTPTABCAFC

Ratings

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Experience

Grade

Trend

DCT

PTAB

CAFC

Analytics

Lawyers

Cases

Ratings Trends

Practice Areas

Recent Dockets

Entered	Case	Description
02/12/25	Natera Inc v. Neogenomics Laboratories Inc 1:23-CV-00629 ( M.D. NC )	Motions Submitted: [364] MOTION to Modify the Court's Construction of the Claim Term "Sequencing the Amplicons" to Chief/Senior District Judge CATHERINE C. EAGLES- (rw) (Entered: 02/12/2025)
02/12/25	Natera Inc v. Neogenomics Laboratories Inc 1:23-CV-00629 ( M.D. NC )	TEXT ORDER issued by Chief/Senior District Judge CATHERINE C. EAGLES on 2/12/25. The Court has reviewed the parties Interim status report. Doc. [382] . It requires no action. If the parties are unable to resolve remaining discovery disputes, a motion is required. The trial is scheduled to begin on October 13, 2025, which is a federal holiday. The Court therefore will conduct jury selection and allow opening statements on Friday, October 10, 2025, with evidence to begin on Tuesday, October 14, 2025. Counsel should hold open October 10-21, 2025, for trial; the court remains of the tentative view that the case can be tried fairly during the week of October 14, but will make a final decision on trial time later, after any summary judgment briefing.(rw) (Entered: 02/12/2025) TEXT ORDER issued by Chief/Senior District Judge CATHERINE C. EAGLES on 2/12/25. The Court has reviewed the parties Interim status report. Doc. [382] . It requires no action. If the parties are unable to resolve remaining discovery disputes, a motion is required. The trial is scheduled to begin on October 13, 2025, which is a federal holiday. The Court therefore will conduct jury selection and allow opening statements on Friday, October 10, 2025, with evidence to begin on Tuesday, October 14, 2025. Counsel should hold open October 10-21, 2025, for trial; the court remains of the tentative view that the case can be tried fairly during the week of October 14, but will make a final decision on trial time later, after any summary judgment briefing.(rw) (Entered: 02/12/2025)
02/11/25	Arbutus Biopharma Corp v. Moderna Inc 1:22-CV-00252 ( D. DE )	ORDER, granting [426] MOTION for Pro Hac Vice Appearance of Attorney Leslie M. Schmidt. Signed by Judge Mitchell S. Goldberg on 2/11/2025. (jfm) (Entered: 02/11/2025)
02/11/25	Arbutus Biopharma Corp v. Moderna Inc 1:22-CV-00252 ( D. DE )	ORDER, granting [424] MOTION for Pro Hac Vice Appearance of Attorney Andrei Iancu and Jeffrey B. Wall. Signed by Judge Mitchell S. Goldberg on 2/11/2025. (jfm) (Entered: 02/11/2025)
02/11/25	Arbutus Biopharma Corp v. Moderna Inc 1:22-CV-00252 ( D. DE )	Pro Hac Vice Fee - Credit Card Payment received for Leslie M. Schmidt. ( re [426] MOTION for Pro Hac Vice Appearance of Attorney Leslie M. Schmidt )( Payment of $ 50, receipt number ADEDC-4612112).(Murray, Travis) (Entered: 02/11/2025)
02/11/25	Arbutus Biopharma Corp v. Moderna Inc 1:22-CV-00252 ( D. DE )	MOTION for Pro Hac Vice Appearance of Attorney Leslie M. Schmidt - filed by Moderna, Inc., ModernaTX, Inc.. (Murray, Travis) (Entered: 02/11/2025)
02/11/25	Raydiant Oximetry Inc v. Alc Medical Holdings LLC 3:25-CV-00392 ( N.D. CA )	DEFENDANT ALC MEDICAL HOLDINGS LLCS ANSWER to Complaint with Jury Demand , COUNTERCLAIM against Raydiant Oximetry, Inc. by ALC Medical Holdings LLC. (Attachments: # [1] Exhibit A - Consulting Agreement, # [2] Exhibit B - Cease and Desist Letter, # [3] Exhibit C - Raydiant - Cobb NDA, # [4] Exhibit D - Offer, Jennifer Cobb, 23November2021 Signed JWC, # [5] Exhibit E - Intro to Patent Attorney, # [6] Exhibit F - IP Email to Patent Attorney with Sketches, # [7] Exhibit G - US11839408, # [8] Exhibit H - Raydiant 1875652, # [9] Exhibit I - Third Party Submission, # [10] Exhibit J - Raydiant 18756713, # [11] Exhibit K - First Office Action 11182024, # [12] Exhibit L - Raydiant Oximetry Oversubscribes Series A_7.5 Million, # [13] Exhibit M - _408 Claim Chart)(Blackburn, Matthew) (Filed on 2/11/2025) (Entered: 02/11/2025) DEFENDANT ALC MEDICAL HOLDINGS LLCS ANSWER to Complaint with Jury Demand , COUNTERCLAIM against Raydiant Oximetry, Inc. by ALC Medical Holdings LLC. (Attachments: # [1] Exhibit A - Consulting Agreement, # [2] Exhibit B - Cease and Desist Letter, # [3] Exhibit C - Raydiant - Cobb NDA, # [4] Exhibit D - Offer, Jennifer Cobb, 23November2021 Signed JWC, # [5] Exhibit E - Intro to Patent Attorney, # [6] Exhibit F - IP Email to Patent Attorney with Sketches, # [7] Exhibit G - US11839408, # [8] Exhibit H - Raydiant 1875652, # [9] Exhibit I - Third Party Submission, # [10] Exhibit J - Raydiant 18756713, # [11] Exhibit K - First Office Action 11182024, # [12] Exhibit L - Raydiant Oximetry Oversubscribes Series A_7.5 Million, # [13] Exhibit M - _408 Claim Chart)(Blackburn, Matthew) (Filed on 2/11/2025) (Entered: 02/11/2025)
02/11/25	Arbutus Biopharma Corp v. Moderna Inc 1:22-CV-00252 ( D. DE )	Pro Hac Vice Attorney Andrei Iancu,Jeffrey B. Wall for Genevant Sciences GmbH added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 02/11/2025)
02/10/25	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	NOTICE by THERAVANCE BIOPHARMA US, INC. of Name Change (CALMANN, ARNOLD) (Entered: 02/10/2025)
02/10/25	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	LETTER ORDER Granting extension of the current case schedule; Parties shall file a joint Claim Construction and prehearing statement by 2/11/2025. Signed by Magistrate Judge Ann Marie Donio on 2/10/2025. (sms2) (Entered: 02/10/2025)